anti-LILRB4 ADC

Anti-LILRB4 ADC is an **antibody-drug conjugate** that combines a humanized monoclonal antibody directed against leukocyte immunoglobulin-like receptor B4 (**LILRB4**, also known as ILT3) with a cytotoxic payload, typically **monomethyl auristatin F** (MMAF), attached via a specialized linker. LILRB4 is highly expressed on monocytic subtypes of **acute myeloid leukemia (AML)** cells (particularly M4 and M5) and not on normal hematopoietic cells, making it a promising target to selectively kill cancer cells while sparing healthy counterparts. Upon binding to LILRB4, the ADC is internalized through receptor-mediated endocytosis, leading to **intracellular release of the cytotoxic payload** and subsequent cell death. Preclinical models show strong anti-tumor efficacy and minimal hematopoietic toxicity, highlighting its potential for monocytic AML treatment[1][4][6].

Other names

anti-LILRB4 antibody-drug conjugateanti-LILRB-4 antibody-drug conjugateanti-LILRB 4 antibody-drug conjugateanti-LILRB4 ADC (DAR-4, prototype constructs)LILRB4-targeting ADCLILRB-4-targeting ADCLILRB 4-targeting ADC